Three's a crowd The often forgotten name in the battle against obesity is Orexigen Therapeutics (NASDAQ: OREX) and its experimental drug Contrave. It's not hard to understand why Orexigen was thrown onto the back burner in investors' minds, since it was going to be a clean one to two full years behind Qsymia and Belviq in making it to market. However, the lack of adequate long-term safety studies in Europe, compounded with abysmal sales for Qsymia and Belviq thus far, could give Contrave the perfect opportunity to steal the show.